Sierra J, Carreras E, Rovira M, Batlle M, Urbano-Ispizua A, Marín P, Besson I, Merino A, Algara M, Cervantes F
Escuela de Hematología Farreras Valentí, Departamento de Medicina, Hospital Clínic i Provincial, Universidad de Barcelona.
Med Clin (Barc). 1995 May 13;104(18):689-94.
Bone marrow transplantation (BMT) from a histocompatible donor is the only curative treatment in chronic myeloid leukemia (CML). Only a minority of patients dispose of an adequate donor from among his/her relatives. The remaining transplant receptors must look to unrelated donors (URD). The experience of the Escuela de Hematología Farreras Valentí (Farreras Valentí School of Hematology, Barcelona, Spain) in BMT from URD in CML in the first chronic phase is herein reported.
Fifteen patients (9 males and 6 females, median age 33 years; range 14-48 years) were transplanted from October 1988 to May 1994. Serologic identity was expressed in the A, B and D loci in 9 cases and minor incompatibility in 6. Conditioning included total body irradiation and cyclophosphamide in 14 patients and busulphan plus cyclophosphamide in 1. Partial and selective T lymphocyte depletion was performed by elutriation in 7 cases.
Primary implant failure was detected in 2 out of 14 risk patients (14%) and secondary failure was observed in 3 out of 12 cases (25%). The actuarial probability of acute graft versus host disease (GVHD) was 55 +/- 15% at 7 weeks with a probability of appearance with an intensity of II-IV of 31 +/- 13%. Five out of 7 patients with a survival of greater than 100 days, developed chronic GVHD (71%). Ten presented fatal complications. In 5 cases, death was due to pulmonary problems. Recurrence of CML was not observed in any of the patients in the series. The probability of disease free survival at 2 years was 30 +/- 12%.
Bone marrow transplantation from an unrelated donor is an effective treatment for a proportion of patients with chronic myeloid leukemia although severe complications are frequent and originate a high mortality.
来自组织相容性供者的骨髓移植(BMT)是慢性髓性白血病(CML)唯一的治愈性治疗方法。只有少数患者能在其亲属中找到合适的供者。其余的移植受者必须寻找无关供者(URD)。本文报告了西班牙巴塞罗那法雷拉斯·巴伦蒂血液学学院(Escuela de Hematología Farreras Valentí)在慢性髓性白血病慢性期从无关供者进行骨髓移植的经验。
1988年10月至1994年5月,对15例患者(9例男性,6例女性,中位年龄33岁;范围14 - 48岁)进行了移植。9例患者在A、B和D位点血清学配型相合,6例存在轻微不相合。14例患者的预处理包括全身照射和环磷酰胺,1例患者采用白消安加环磷酰胺。7例患者通过淘洗进行部分和选择性T淋巴细胞清除。
14例有风险的患者中有2例(14%)出现原发性植入失败,12例中有3例(25%)出现继发性失败。急性移植物抗宿主病(GVHD)的精算概率在7周时为55±15%,II - IV级强度的出现概率为31±13%。7例存活超过100天的患者中有5例发生慢性GVHD(71%)。10例出现致命并发症。5例患者死于肺部问题。该系列中没有患者出现CML复发。2年无病生存概率为30±12%。
无关供者的骨髓移植对一部分慢性髓性白血病患者是一种有效的治疗方法,尽管严重并发症频繁发生且导致高死亡率。